Log in

NASDAQ:RVNC - Revance Therapeutics Stock Price, Forecast & News

$15.99
-0.46 (-2.80 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$15.40
Now: $15.99
$16.55
50-Day Range
$15.00
MA: $16.27
$20.35
52-Week Range
$9.88
Now: $15.99
$20.83
Volume886,971 shs
Average Volume920,885 shs
Market Capitalization$721.31 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RVNC
CUSIPN/A
Phone510-742-3400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.73 million
Book Value$3.94 per share

Profitability

Net Income$-142,570,000.00
Net Margins-3,745.97%

Miscellaneous

Employees170
Market Cap$721.31 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive RVNC News and Ratings via Email

Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.


Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics Inc (NASDAQ:RVNC) issued its earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.96). The biopharmaceutical company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.40 million. Revance Therapeutics had a negative return on equity of 87.59% and a negative net margin of 3,745.97%. View Revance Therapeutics' Earnings History.

When is Revance Therapeutics' next earnings date?

Revance Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Revance Therapeutics.

What price target have analysts set for RVNC?

8 brokers have issued twelve-month target prices for Revance Therapeutics' shares. Their forecasts range from $20.00 to $50.00. On average, they anticipate Revance Therapeutics' stock price to reach $29.86 in the next year. This suggests a possible upside of 86.7% from the stock's current price. View Analyst Price Targets for Revance Therapeutics.

What is the consensus analysts' recommendation for Revance Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Revance Therapeutics.

What are Wall Street analysts saying about Revance Therapeutics stock?

Here are some recent quotes from research analysts about Revance Therapeutics stock:
  • 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (10/17/2019)
  • 2. Mizuho analysts commented, "We estimate a floor valuation of $17/share which includes: additional dilutive financing, Fosun deal, no credit for therapeutics, poor performance in U.S. aesthetics. With credit for therapeutics and fair aesthetic assumptions, we see ~180%+ upside to our base case $37 PT." (4/24/2019)
  • 3. HC Wainwright analysts commented, "Our $25 price target for Revance is based on our sum of the parts NPV valuation based on each of RT-002’s targeted indications. Our DCF model utilizes a WACC-derived discount rate of 12.2% (Beta of 1.4, equity risk premium of 6.7%). We adjust each indication for probability of success with glabellar lines at 85%, cervical dystonia at 80%, plantar fasciitis at 25%, chronic migraine at 35% and upper limb spasticity at 80%." (2/14/2019)

Has Revance Therapeutics been receiving favorable news coverage?

Press coverage about RVNC stock has been trending very positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Revance Therapeutics earned a news impact score of 4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Revance Therapeutics.

Are investors shorting Revance Therapeutics?

Revance Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totalling 5,830,000 shares, an increase of 6.0% from the October 31st total of 5,500,000 shares. Based on an average daily trading volume, of 373,800 shares, the days-to-cover ratio is presently 15.6 days. Currently, 15.0% of the shares of the company are short sold. View Revance Therapeutics' Current Options Chain.

Who are some of Revance Therapeutics' key competitors?

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), Intercept Pharmaceuticals (ICPT), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Merck & Co., Inc. (MRK), CVS Health (CVS), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP) and Viking Therapeutics (VKTX).

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the folowing people:
  • Mr. L. Daniel Browne, Co-Founder, Pres, CEO & Director (Age 57)
  • Mr. Tobin C. Schilke, CFO & Principal Accounting Officer (Age 44)
  • Dr. Abhay Joshi, Chief Operating Officer (Age 56)
  • Ms. Caryn Gordon McDowell, Sr. VP, Gen. Counsel & Corp. Sec. (Age 49)
  • Ms. Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rice Hall James & Associates LLC (2.45%), State Street Corp (2.27%), Point72 Asset Management L.P. (0.48%), Rhenman & Partners Asset Management AB (0.39%), California State Teachers Retirement System (0.15%) and California Public Employees Retirement System (0.15%). Company insiders that own Revance Therapeutics stock include Cyril Allouche, L Daniel Browne, Lauren P Silvernail and Phyllis Gardner. View Institutional Ownership Trends for Revance Therapeutics.

Which major investors are selling Revance Therapeutics stock?

RVNC stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, Rhenman & Partners Asset Management AB, Russell Investments Group Ltd. and Barclays PLC. Company insiders that have sold Revance Therapeutics company stock in the last year include Cyril Allouche and L Daniel Browne. View Insider Buying and Selling for Revance Therapeutics.

Which major investors are buying Revance Therapeutics stock?

RVNC stock was bought by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Point72 Asset Management L.P., State Street Corp, Voloridge Investment Management LLC, Nisa Investment Advisors LLC, California Public Employees Retirement System, Public Employees Retirement System of Ohio and Quadrant Capital Group LLC. View Insider Buying and Selling for Revance Therapeutics.

How do I buy shares of Revance Therapeutics?

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $15.99.

How big of a company is Revance Therapeutics?

Revance Therapeutics has a market capitalization of $721.31 million and generates $3.73 million in revenue each year. The biopharmaceutical company earns $-142,570,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis. Revance Therapeutics employs 170 workers across the globe.View Additional Information About Revance Therapeutics.

What is Revance Therapeutics' official website?

The official website for Revance Therapeutics is http://www.revance.com/.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]


MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  317 (Vote Outperform)
Underperform Votes:  299 (Vote Underperform)
Total Votes:  616
MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe RVNC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVNC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel